SNGX Soligenix, Inc.

-0.01  -0%
Previous Close 2.36
Open 2.30
Price To book 2.22
Market Cap 13.33M
Shares 5,672,000
Volume 124,525
Short Ratio 1.22
Av. Daily Volume 634,232

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial complete.
Radiation Enteritis
Phase 3 data due 2H 2017.
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Seek to obtain FDA agreement on Phase 2b/3 protocol in 1H 2017
SGX942 (dusquetide)
Oral Mucositis in Patients with Head & Neck Cancer
Phase 3 initiation due 1H 2017 with data due 2H 2018 - pending funding.
Pediatric Crohn’s Disease

Latest News

  1. Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
  2. SNGX: SGX942: Cancer Control is an “Added Bonus” for OM Treatment
  3. Soligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results
  4. With Two Phase III Trials Operational & Significant Financial Leverage, Soligenix Shining
  5. Soligenix Receives Japanese Patent for ThermoVax® Vaccine Heat Stabilization Platform Technology
  6. Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
  7. Today's Research Reports on Biotech Stocks to Watch: Soligenix and MannKind
  8. Efficacy Results from Soligenix's Ricin Toxin Vaccine Program to be Presented at the 20th Annual Conference on Vaccine Research
  9. Soligenix to Present at the World Orphan Drug Congress
  10. Statistically Significant Data from Late Stage Clinical Assets & Continued Funding from the Government Positions Soligenix Attractively for a Potential Suitor
  11. Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
  12. Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results
  13. Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 19th Annual Superbugs & Superdrugs Conference
  14. Soligenix (SNGX): A Key Player in the Biodefense Space
  15. Soligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting
  16. SNGX: Potential Expansion of Synthetic Hypericin into Psoriasis
  17. Soligenix Receives European Patent for Formulation of Synthetic Hypericin to Treat Psoriasis
  18. Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
  19. Soligenix to Present at 9th Annual Biotech Showcase Conference
  20. Soligenix (SNGX): SGX942 (Dusquetide) Could be A Game Changer for the Treatment of Oral Mucositis